EARNIX
11.1.2023 18:37:39 CET | Business Wire | Press release
Earnix, the market-leading provider of mission-critical cloud-based intelligent real-time, dynamic pricing and rating solutions for insurers and banks, today announced it is appointing insurance and fintech industry veteran, Robin Gilthorpe, as its new Chief Executive Officer effective February 1, 2023. Mr. Gilthorpe will be taking over the helm from Mr. Udi Ziv, who served as the company’s CEO over the past six years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005784/en/
Robin Gilthorpe, CEO, Earnix (Photo: Business Wire)
Robin Gilthorpe, a veteran of the finance and insurance industries, brings to the role over 25 years of experience as a successful business leader. Throughout his career, Mr. Gilthorpe has held numerous executive leadership roles at leading technology and insurance companies such as TIBCO, Vertexone, Watersmart Software, DataSynapse and ESW Capital. In his most recent role at Insurtech innovator Salty, Gilthorpe served as Chief Operating Officer, generating a nine-figure outcome in sale to CDK Global.
“I am thrilled to be joining Earnix at this crucial time in the global economy,” said Robin Gilthrope, incoming CEO at Earnix. “Financial services companies across the globe are seeking intelligent operations to ensure they can offer real-time, dynamic solutions, to better serve customers, enabling them to be more agile, nimble, attentive, and responsive. Today’s end-customer demands unparalleled experience, alongside highly personalized and customizable solutions. Earnix solutions serve as the go-to platform for financial services companies to address the growing demands of the world’s leading financial and insurance companies.”
His hiring comes on the heels of a period of growth for Earnix led by exiting CEO Udi Ziv. Mr. Ziv joined Earnix in 2017 and in his six years with the firm has led the company to consistent growth, achieving Unicorn status and important strategic alliances including forging the recently announced strategic partnership with Guidewire as well as engagements with USAA, MAPFRE, IAG, Liberty Mutual, US Bank, Lloyd’s Banking Group, and many more. Mr. Ziv built a strong team of leaders positioned to drive the company’s continued growth. Udi will serve as one of the industry experts on the Earnix Board of directors.
“We are proud to welcome Robin to the Earnix family, and believe that his experience in building global, international companies, alongside the growing demand for Earnix’s suite of real-time, dynamic, composable Intelligent InsurOps solutions, will lead Earnix to significant growth over the next few years, and bring Earnix to international market leadership, with its real-time operation platform for the largest insurance companies and banking institutions,” said Erel Margalit, JVP Founder & Executive Chairman and Earnix's Chairman of the Board, “We want to thank Udi for his important role, over the last few years. With its growing presence in North America, Europe, Asia Pacific, and Israel, Earnix will continue to strive to become the category leader, in the real-time AI usage-based insurance and banking industry.”
“I’ve very much enjoyed my tenure at Earnix, leading the company to consistent year over year growth, and strongly believe in our people and products as a change agent for financial services companies,” Udi Ziv, exiting CEO, Earnix, said. “I believe now is the time to move on to my next endeavor as the company prepares for its next stage of international expansion. I firmly believe I am leaving the company in very capable hands with Robin and expect that the company will continue the rapid global growth Earnix has experienced in the last few years.”
About Earnix
Earnix is the premier provider of mission-critical composable and cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for Insurers and Banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix shareholders include JVP, Insight Partners, IGP, and Vintage Investment Partners.
For more information please visit: earnix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005784/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
